Clinical Grade iPS Cells: Need for Versatile Small Molecules and Optimal Cell Sources  by Wu, Yan-Ling et al.
Chemistry & Biology
ReviewClinical Grade iPS Cells: Need
for Versatile Small Molecules
and Optimal Cell SourcesYan-Ling Wu,1,6 Ganesh N. Pandian,2,6 Yan-Ping Ding,1 Wen Zhang,3 Yoshimasa Tanaka,4 and Hiroshi Sugiyama2,5,*
1Virus Inspection Department, Zhejiang Provincial Center for Disease Control and Prevention, 630 Xincheng Road, Hangzhou 310051, China
2Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Sakyo, Kyoto 606-8502, Japan
3Department of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, Zhejiang University of Technology, 18 Chaowang Road,
Hangzhou 310014, China
4Center for Innovation in Immunoregulative Technology and Therapeutics, Graduate School of Medicine, Kyoto University,
Kyoto 606-8501, Japan
5Department of Chemistry, Graduate School of Science, Kyoto University, Sakyo, Kyoto 606-8501, Japan
6These authors contributed equally to this work
*Correspondence: hs@kuchem.kyoto-u.ac.jp
http://dx.doi.org/10.1016/j.chembiol.2013.09.016
Adult mammals possess limited ability to regenerate their lost tissues or organs. The epoch-making strategy
of inducing pluripotency in somatic cells incorporates multiple applications in regenerative medicine.
However, concerns about the clinical translation of induced pluripotent stem (iPS) cells still exist because
of the occurrence of aberrancies, even in genome integration-free methods. As cellular reprogramming is
multi-gene-oriented, versatile, bioactive small molecules could concomitantly modulate the transcriptional
machinery and aid the generation of clinical grade iPS cells. The availability of optimal cell sources has addi-
tional influence on the clinical translation of iPS cells. Herein we provide a critical overview of methods and
cell sources available for iPS cell production. We think the review will be a useful resource for researchers
who aim to develop small molecules for speeding up the journey of iPS cells from the laboratory to the clinic.Cellular regeneration is a widely variable biological feature of all
living organisms. In humans, who inherently lack the capacity
to regenerate lost tissues or organs, the physical plasticity of
embryonic stem cells (ESCs) and their ability to generate the
desired cell types under culture conditions offer potential clinical
solutions (Evans and Kaufman, 1981). However, ESC-derived
cells may lead to immune-mediated rejection because the
antigens expressed in the recipient patients are different. An
alternative method, termed somatic cell nuclear transfer, or
SCNT, uses patient-derived stem cells that are genetically iden-
tical to the donor nucleus. Gurdon successfully demonstrated
this technique in frogs (Gurdon, 1962), which changed the
scientific view that the fate of the specialized cells is irreversible,
and Wilmut and colleagues substantiated the potential of this
technique by cloning a mammal (Wilmut et al., 1997). However,
attempts to use this technique in humans have only recently
met with success after the development of refined protocols
that circumvent major roadblocks, such as early embryonic
arrest and suboptimal activation of key factors (Tachibana
et al., 2013). Another issue in ESC research is that it is ethically
controversial because experimental use of an early-stage em-
bryo could potentially cause a human life to be destroyed.
About five decades later, on the basis of early ground-
breaking work, Takahashi and Yamanaka (2006) provided a
solution to the sourcing issues associated with ESCs by gener-
ating induced pluripotent stem (iPS) cells via the forced expres-
sion of four transcription factors. This discovery was proclaimed
to have the potential to ease the controversy and ethical
dilemmas associated with ESCs and to effectively bypass the
problem of immune rejection. Consequently, the two pioneersChemistry & Biology 2of cellular reprogramming, Dr. John Gurdon and Dr. Shinya
Yamanaka, won the 2012 Nobel Prize in Physiology or Medicine.
Despite the exciting progress made under laboratory conditions,
several barriers still hinder the transfer of iPS cell technology to
the clinic. For example, there is increasing awareness of the
similarities between iPS cells and cancer cells, and the genetic
methods used to generate iPS cells can be a huge setback
during evaluation of study protocols by international regulatory
bodies (Barrilleaux and Knoepfler, 2011). The current iPS
cell-engineering process may produce cells of variable quality
(Gore et al., 2011; Kim et al., 2010). Similarly to any other prod-
uct, cost and the time consumed are also significant concerns
for the generation and marketing of clinical grade iPS cells
(CGiPS) (Barrilleaux and Knoepfler, 2011). It may take months
to validate and differentiate iPS cells prior to their clinical use.
Hence, these cells are probably not ideal for the most acute
and/or life-threatening illnesses and injuries that require imme-
diate treatment. Current batch-prepared ESC-based products
can be cheaper than iPS cells and are readily available. Hence,
the expectation that iPS cells will be phased out and will replace
ESCs has yet to be realized.
In this regard, the rapid generation of iPS cells using a com-
bination of small molecules has attracted immense interest
because this approach would eliminate the risk of genetic modi-
fication (Pandian et al., 2012a). Experimental practice thus far
suggests that small molecules are easy to handle and could be
readily available. Also, small molecules may have little or no
side effects after the desired cellular phenotype is achieved.
However, chemical reprogramming approaches may also intro-
duce genetic or epigenetic abnormalities into the resultant iPS0, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1311
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straightforward, owing to the dynamic epigenome. Thus, there
is a demand to design and synthesize tailor-made small mole-
cules with the specific mechanism of action, such as effect on
epigenetic activity, to control the complicated gene networks
associated with pluripotency. Also, the choice of cell source
plays a pivotal role in the development of appropriate small
molecules to generate CGiPS. Herein we give an overview of
the various cell sources and reprogramming protocols available
for deriving iPS cells with emphasis on cellular reprogramming
with small molecules alone. The challenges and opportunities
of developing innovative strategies that could potentially send
the somatic cells back in time to an embryonic (pluripotent) state
and/or push them into totally new types of cells are also briefly
discussed.
Routes to the Efficient Induction of Pluripotency
in Somatic Cells
The scientific principles underlying cellular reprogramming and
the technologies associated with it have been under develop-
ment for the past six decades. Some of the early successes
include demonstration that a nucleus can be isolated and
transplanted from late-stage embryos into enucleated oocytes
(Briggs and King, 1952), establishment of immortal pluripotent
cell lines from tumors of germ cell origin (Kleinsmith and Pierce,
1964), isolation of pluripotent cells directly from the embryo
(Evans and Kaufman, 1981), and production of myofibers from
fibroblast cell lines infected with retroviral vectors harboring
the skeletal muscle factor MyoD (Davis et al., 1987). Some of
these landmark early experiments provided a platform that
inspired Takahashi and Yamanaka to screen for and identify
four reprogramming factors in mouse fibroblasts (Oct-3/4,
Sox2, Klf4, and c-Myc) that are essential for ESCs (Takahashi
and Yamanaka, 2006). A milestone was later reached when
iPS cells derived from human somatic cells were established
(Takahashi et al., 2007; Yu et al., 2007). The iPS cells producing
high levels of c-Myc protein often lead to the development of
tumors, probably because c-Myc encourages not only self-
renewal but also tumorigenesis. A subsequent study showed
that pluripotency could be conferred on differentiated mouse
and human cells without c-Myc (Nakagawa et al., 2008), but
with low induction efficiency. The risk of tumor formation led
researchers to develop integration-free strategies by employing
adenoviruses, Sendai virus, plasmids, and protein-based proto-
cols (Ban et al., 2011; Kim et al., 2008, 2009; Maherali et al.,
2007; Mali et al., 2008; Mathieu et al., 2013; Okita et al., 2007,
2008; Park et al., 2008; Seki et al., 2010; Shu et al., 2013;
Si-Tayeb et al., 2010; Stadtfeld et al., 2008; Zhang et al., 2011).
Nevertheless, induction efficiency had to be compromised in
these nonintegrative methods.
Rossi and colleagues developed a better approach to reprog-
ramming human fibroblasts into iPS cells using a synthetic
mRNA (Warren et al., 2010). This strategy is superior to virus-
mediated gene transfer protocols regarding both conversion
efficiency and kinetics. A miRNA-based strategy successfully
reprogrammed mouse and human somatic cells to pluripotent
cells (Anokye-Danso et al., 2011). The PiggyBac Transposon
Vector–based method (System Biosciences, Mountain View,
CA) is another zero-footprint method for iPS cell generation1312 Chemistry & Biology 20, November 21, 2013 ª2013 Elsevier Ltd(Woltjen et al., 2009). The popular nonintegrating methods,
such as the episomal plasmid-based method and the Sendai
virus-based method are still highly favored to reprogram
different cell types (Ban et al., 2011; Okita et al., 2011; Yu
et al., 2009). Synthetic mRNA-based protocols have maximum
efficiency (about 36-fold) over the original retrovirus-mediated
system for delivering reprogramming factors. However, the
lability of RNA and the undesired induction of innate antiviral
defense pathways remain a barrier to their clinical use. Hence,
there is a need to improve the established protocols and/or to
develop clinically friendly strategies for achieving CGiPS.
Cellular reprogramming with chemicals alone is a strategy
thought to have better clinical prospects because it avoids ge-
netic manipulation and could be readily available. Currently
available reprogramming protocols to achieve usable iPS cell
lines have their own induction efficiency and time frame advan-
tages and disadvantages (Table 1). Numerous reports are now
available on better ways to generate clinically useful iPS cells
from various cell sources (Loh et al., 2009) and associatedmech-
anisms (Gutierrez-Aranda et al., 2010; Lee et al., 2012; Lu et al.,
2012), with remarkable progress made over a short period
(Figure 1).
Large Impact of Small Molecules in the Generation
of iPS Cells
Small molecules have already been successfully employed in
the generation of iPS cells. Shi and colleagues identified small
molecules that could enhance the reprogramming efficiency of
the genetic approach in mouse cells (Shi et al., 2008a). Dual
inhibition (2i) of the signaling pathways (MEK andGSK3) reduced
the time frame required for reprogramming mouse embryonic
fibroblasts (MEFs) and neural precursors into pluripotent cells
(Silva et al., 2008) even in the absence of Sox2 and c-Myc. Like-
wise, small molecules that inhibit the signaling factors asso-
ciated with differentiation could either enhance the efficiency
of iPS cell generation or substitute one or more reprogramming
factors in mouse cells (Lyssiotis et al., 2009; Pandian and
Sugiyama, 2012; Shi et al., 2008a, 2008b; Yuan et al., 2011).
Identification of an Oct-3/4 activator (OAC1) in MEFs suggested
that even Oct-3/4 could be substituted (Li et al., 2012). Small-
molecule-mediated inhibition of mammalian target of rapamycin
facilitated the reprogramming of MEFs into iPS cells (Chen et al.,
2011). Two-factor reprogramming of human neural stem cells
into pluripotency could be achieved with forskolin, a diterpene
activator of adenylate cyclase (Hester et al., 2009).
Dynamic chromatin modifications facilitate the establishment
andmaintenance of pluripotency in somatic cells. A combination
of the G9a histone methyltransferase inhibitor BIX-01294 and
the L-channel calcium agonist Bayk8644 artificially induced
pluripotency in the absence of Sox2 and c-Myc (Mikkelsen
et al., 2008). Small-molecule inhibitors of chromatin-modifying
enzymes such as DNA methyltransferase and histone deacety-
lase (HDAC) improved reprogramming efficiency by inducing
changes in global-level changes in gene expression (Li et al.,
2009; Lin et al., 2009; Mali et al., 2010). HDAC inhibitors, such
as suberoylanilide hydroxamic acid (SAHA) and trichostatin A,
increase the SCNT-mediated reprogramming efficiency by
about 5-fold in a concentration- and time-dependent manner
(Kishigami et al., 2006). Among the several small-moleculeAll rights reserved
Table 1. Comparison of Various Methods to Generate iPS Cells
Reprogramming Methods Cells
Efficiency
(%)
Time to Generate
Usable iPS
Cell Line
Major
Drawback Cost
Clinical
Safety References
Integrating methods
Virus-based MEF 0.01 4 weeks teratoma
formation
medium medium Takahashi and
Yamanaka, 2006;
Takahashi et al., 2007
Retrovirus HDF
Lentivirus MEF, FF 0.001–0.01 low Yu et al., 2007;
Hotta et al., 2009
Non-virus-based
Transposons
MEF, HDF 0.01 3 weeks low efficiency medium medium Woltjen et al., 2009
Nonintegrating methods
Virus-based
Adenovirus TTF, fetal
liver
0.0001,
0.0006
30 days low efficiency high medium Stadtfeld et al., 2008
Sendai virus CB cells 0.01 28 days low efficiency high medium Ban et al., 2011
Non-virus-based
Protein HNF 0.001 56 days slow process high medium Kim et al., 2009
mRNA BJ
fibroblasts
>1 18 days stability and
trigger innate
antiviral defense
pathway
high medium Warren et al., 2010
miRNA BJ
fibroblasts
0.021 14–18 days possibility of
integrated vector,
subfragments
high medium Anokye-Danso et al.,
2011
Episomal vectors foreskin
fibroblasts
0.01–1 17–21 days high medium Yu et al., 2009;
Okita et al., 2011
Combined small-molecule approach
OSKM+PD0325901 +
CHIR99021
mNSC 0.11 30 to 40 days problems
associated with
the presence
of retrovirus
medium low Silva et al., 2008
O+NaB+PS48+A-83-
01+PD0325901
NHEK 0.00004 Zhu et al., 2010
O+A-83-01+AMI-5 MEF 0.02 Yuan et al., 2011
OS+VPA HDF 0.5 Huangfu et al., 2008
Chemicals alone MEF 0.2 40 days not determined low high Hou et al., 2013
CB, cord blood; FF, fetal fibroblast; HDF, human dermal fibroblast; HNF, human neonatal fibroblast; K, Klf4; M, c-Myc; MEF, mouse embryonic
fibroblast; NaB, sodium butyrate; NHEK, normal human epidermal keratinocyte; mNSC, mouse neural stem cell; O, Oct4; S, Sox2; TTF, tail-tip
fibroblast; VPA, valproic acid.
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HDAC-inhibiting valproic acid and sodium butyrate led to a dra-
matic increase in reprogramming efficiency (about 100-fold)
(Liang et al., 2010; Shi et al., 2008a) (Figure 2A). Ubiquitously
used chemicals enhanced the generation of both mouse and
human iPS cells (vitamin C; Esteban et al., 2010) and the reprog-
ramming efficiency of MEFs through hyperosmosis, which
reduced global demethylation level (sodium chloride; Xu et al.,
2013). The chemical element lithium demonstrated a surprising
effect of enhancing the reprogramming efficiency of both
MEFs and human umbilical vein endothelial cells (HUVECs)
into iPS cells (Wang et al., 2011a). Induction of pluripotency
using only a single gene and a combination of small molecules
inmouse and human cells has brought us a step closer to cellularChemistry & Biology 2reprogramming with small molecules alone (Li et al., 2011; Zhu
et al., 2010). Deng and colleagues finally accomplished this
complex feat by using seven small molecules to generate chem-
ically induced iPS cells (CiPS) cells from mouse somatic cells
with an induction efficiency of about 0.2% (Hou et al., 2013).
We think that generating CiPS cells from human somatic cells
will be achieved in the near future through the identification
of small molecules that activate key developmental factors
such as OCT4. Recent progress suggests that a number of
chemicals are capable of enhancing reprogramming efficiency
of fibroblasts into pluripotent stem cells (Figure 2B, Table 2),
suggesting that there is significant room for improvement in
the current protocols for and optimization of complete chemical
reprogramming.0, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1313
Figure 1. A Graphical Overview of SomeHallmark Studies of iPS Cells Published between 2006 and July 2013 Carried Out inMouse or Human
Cells
[H], human; iPSC, induced pluripotent stem cell; K, Klf4; L, Lin-28; M, c-Myc; [M], mouse; N, Nanog; NaB, sodium butyrate; NP, neural progenitor; NSC,
neural stem cell; O, Oct-4; S, Sox2; UTF, undifferentiated cell transcription factor.
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Figure 2. Small Molecules with Reprograming Effects
(A) Histone deacetylase (HDAC) enhances reprogramming efficiency. The efficiency of reprogramming of somatic cells into the pluripotent state using the four
transcription factors improves by more than 100-fold with HDAC inhibitor (HDACi) especially valproic acid than that without HDACi.
(B) Small molecule inhibitors for factors blocking the conversion of somatic cells to pluripotent stem cells. Some commercially available small molecules known to
improve reprogramming efficiency by inhibiting signaling pathways, such as transforming growth factor TGF-b, GSK-b, MEK, RAR-a, ROCK, p53 (Feng et al.,
2008; Kawamura et al., 2009; Wang et al., 2011b), and chromatin-modifying enzymes, such as histone methylases, HDACs, and DNA methyltransferases
(DNMTs), are shown.
GSK-b, glycogen synthase kinase 3b; LSD, lysine-specific demethylase; MEK, mitogen-activated protein kinase kinase; PDK, protein kinase; RAR, retinoic acid
receptor; ROCK, Rho-associated kinase; TGF-b, transforming growth factor b.
Chemistry & Biology 20, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1315
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Table 2. Chemicals Harnessed for the Generation of iPS Cells
Chemical Function Cells Reference
Forskolin  Diterpene activator of adenylate cyclase Human neural stem cells (Hester et al., 2009)
DZNeP  Global histone methylation inhibitor MEF (Hou et al., 2013)
Apigenin  Downregulation of a H3K4-specific
histone methylase
MEF (Chen et al., 2010)
Vitamin C Enhances the generation of mouse
and human iPSC
MEF, HDF (Esteban et al., 2010)
PS48
Cl
O
OH
Phosphoinositide-dependent protein
kinase-1 activator
Primary NHEK (Zhu et al., 2010)
Rapamycin Mammalian target of rapamycin inhibitor MEF (Chen et al., 2011)
Lithium Downregulation of a H3K4-specific
histone methylase
MEF, HUVEC (Wang et al., 2011a)
Oct-4 activator (OAC1)  Inhibition of the p53-p21 pathway or
activation of the Wnt-b-catenin signaling.
MEF (Li et al., 2012)
NaCl Hyper osmosis and reduction of global
demethylation level
MEF (Xu et al., 2013)
DZNeP, 3-deazaneplanocin; H3K4, histone H3 lysine 4; HDF, human dermal fibroblast; HUVEC, human umbilical vein endothelial cell; MEF, mouse
embryonic fibroblast; NHEK, normal human epidermal keratinocyte.
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Figure 3. Suberoylanilide Hydroxamic Pyrrole-Imidazole
Polyamides and Pluripotency Genes
(A) Chemical structures of the suberoylanilide hydroxamic pyrrole-imidazole
polyamides SAHA-PIP D, -E, -J, and -O and their simplified illustrations.
Chemistry & Biology 2
Chemistry & Biology
ReviewProgrammed Multitarget Molecules for Cellular
Reprogramming: Current Progress and Future
Challenges
Generation of iPS cells depends upon the concomitant expres-
sion of multiple factors; thus, many small molecules might be
needed to achieve reprogramming using chemicals. Develop-
ment of innovative small molecules that have one or more func-
tional activities is an alternative option. Hairpin pyrrole–imidazole
polyamides (PIPs) are programmable synthetic molecules that
can bind to theminor groove of DNAwith an affinity that is similar
to that of natural transcription factors (Kashiwazaki et al., 2012;
Pandian and Sugiyama, 2012, 2013). PIPs are versatile small
molecules and could be developed for use in many applications,
as they have flexible sites for covalent attachment to molecules,
such as fluorescent dyes and/or some enzyme inhibitors (Pan-
dian and Sugiyama, 2012; Vaijayanthi et al., 2012; Vaijayanthi
et al., 2013).
In 2011, the Sugiyama group achieved a unique break-
through by synthesizing a small-molecule class, called SAHA-
PIP, by conjugating PIP with SAHA. As mentioned earlier,
SAHA has potent inhibitory activity against HDAC1, the chro-
matin-modifying enzyme that regulates pluripotency and line-
age-specific transcriptional networks (Huangfu et al., 2008;
Kidder and Palmer, 2012). Hence, a series of 16 SAHA-PIPs
that could cause differential gene activation were screened to
identify the bioactive SAHA-PIPs that can modulate the endog-
enous expression of standard reprogramming factors in MEFs.
Interestingly, 4 of the 16 SAHA-PIPs (D, E, J, and O; Figure 3)
distinctively induced the expression of Oct-3/4, Nanog, Sox2,
Klf4, and c-Myc (Pandian et al., 2011). SAHA-PIP-mediated
gene induction occurred by establishing transcriptionally
permissive chromatin, including Lys9 and Lys14 acetylation
and Lys4 trimethylation of histone H3. Modifications of the
chemical architecture of one the SAHA-PIPs (Figure 3E), which
induced Oct-3/4 and Nanog expression, resulted in the
improvement of expression levels; however, the effect was
only marginal (Pandian et al., 2012b). Nevertheless, the scope
of the improvement demonstrated in this work confirmed the
possibility of tailoring SAHA-PIPs and improving their efficacy.
Subsequently, a novel library of SAHA-PIPs with improved
recognition of GC-rich sequences revealed a potent SAHA-
PIP that can induce multiple pluripotency genes in just 24 hr
and at nanomolar concentrations. A microarray analysis re-
vealed that this SAHA-PIP, designated ‘‘d,’’ switched the tran-
scriptional network from the fibroblast state to the pluripotent
state. This novel small molecule also rapidly overcame the
mesenchymal–epithelial transition (MET) stage, which is an
important rate-limiting step during the dedifferentiation of the
somatic genome (Pandian et al., 2012a; Polo and Hochedlinger,
2010). More details of certain SAHA-PIPs and their target
pluripotency genes are shown in Figure 3.
As the clinical utility of iPS cells improves with the decrease
in the number of reprogramming factors, the identification of(B) SAHA-PIPs induce site-specific acetylation, which in turn triggers the
transcription of c-Myc (D), Oct-3/4 (E), Sox2 (J), and Klf4 (O).
(C) SAHA-PIP d triggers the core pluripotency gene network, but not Klf4, to
initiate cellular reprogramming via the downregulation of the mesenchymal
markers and the upregulation of epithelial markers (modified version of
Pandian et al., 2012a).
0, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1317
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tency genes may lead to the efficient generation of pluripotent
stem cells. A recent report showed that subtle modification in
the structure of SAHA could alter the specificity of SAHA-PIP
d toward different HDAC enzymes (Saha et al., 2013). A system-
atic approach is thus in demand to mimic the natural cellular
environment and design preprogrammed chromatin-remodeling
PIPs to bypass the conventional routes to achieving pluripo-
tency. Although the concept of a small-molecule multifactor
is promising, several bottlenecks, such as cell permeability
issues related to small molecules, as well as the identification
of appropriate cell sources, are essential because the epige-
nome of each cell type is different.
Essential Role of Optimal Cell Sources for the Efficient
Generation of CGiPS Cells
The point from which one starts defines the time and the way in
which one needs to reach a destination. From this perspective,
not only the route of reprogramming, but also the choice of cell
sources have a significant impact on the probability of reaching
the desired destination of clinically useful iPS cells. Furthermore,
the use of less-invasive methods to obtain source cells can
generate readily available, larger amounts of cells (Ohmine
et al., 2012). Accordingly, human keratinocytes are a good
source from which to derive iPS cells with high efficiency, as
they can be obtained by simply plucking a patient’s hair (Aasen
et al., 2008). Gingival fibroblasts (GFs) are the main components
of the gingival connective tissues and play a cardinal role in oral
wound-healing. Moreover, their culture is also relatively simple,
as GFs adhere well, spread onto the culture plates, and prolifer-
ate rapidly, even under ordinary culture conditions (Egusa et al.,
2010). Hence, GFs are an ideal source for (1) the generation of
iPS cells that can be translated clinically in dentistry and (2)
the establishment of an iPS cell bank that could be harnessed
for comprehensive medical applications. One of the barriers
that hinders the clinical translation of iPS cells is the need to
xenoculture cells on feeder layers. Anchan and colleagues
generated iPS cells within 5–7 days from mouse and human
amniocytes using retroviral vectors encoding either one of the
four factors or two factors, and pluripotency could be main-
tained over mitotically inactivated amniocytes. Interestingly,
the efficiency of iPS cell generation from amniocytes was about
10-fold higher than that observed for iPS cells generated from
MEFs or human dermal fibroblasts (Anchan et al., 2011). With
the derivation of cellular components from a single donor, the
safety concerns associated with xenoculture can be annulled.
Only two factors (Klf4 and c-Myc) were sufficient to achieve
amniocyte-derived iPS cells that could be differentiated into
the three germ layers.
Panopoulos and colleagues reported that iPS cells could be
achieved rapidly (in just 6 days) from HUVECs with greater
efficiency (approximately 300-fold higher) compared to human
fibroblasts (Panopoulos et al., 2011). Reprogramming of
HUVECs under hypoxic conditions and in the presence of a
TGF-b inhibitor had better efficiency (about 2.5-fold) than those
reprogrammed under standard conditions. HUVECs are also
an attractive somatic source for therapeutic applications. Like-
wise, iPS cells generated from human cord blood (Giorgetti
et al., 2009) could be a stored and readily available human1318 Chemistry & Biology 20, November 21, 2013 ª2013 Elsevier Ltdleukocyte antigen–type somatic cell. The adipose tissue that is
available abundantly in the body is another preferred cell source
from which to derive iPS cells. Human and mouse adipose-
derived stem (ADS) cells were reprogrammed into a pluripotent
state under standard feeder-dependent conditions with high
efficiency until the 1.5% level was reached (Sugii et al., 2011).
ADS cells can be developed for therapeutic use, as they prolifer-
ate rapidly and differentiate into adipocytes, osteocytes, chon-
drocytes, and myocytes (Gimble et al., 2007). Employment of
cord blood cells, HUVECs, or human amniocytes as starting
cells for reprogramming also has limitations. These cells are
not always available for patients and individuals who manifest
certain disease symptoms and demand the use of personalized
iPS cell–based regenerative therapy. Recently, Wang and
colleagues reprogrammed epithelial-like human urine cells into
neural progenitors using episomal vectors (Wang et al., 2013).
Journey toward CGiPS Cells and Major Roadblocks
An increasing number of studies in mouse models suggest the
therapeutic potential of iPS cells. One such study showed that
when iPS-derived neurospheres preevaluated as ‘‘safe’’ are
transplanted into a severe combined immunodeficiency mouse
brain, they produce functional nerve cells under in vitro condi-
tions with no tumor formation (Tsuji et al., 2011). Such safe
iPS-cell-derived cells should be employed for transplantation
therapies. Ye and colleagues successfully reprogrammed skin
fibroblasts from a homozygous b-thalassemia patient into
pluripotent cells, and the derived iPS cells differentiated into
hematopoietic cells that synthesized hemoglobin (Ye et al.,
2009). In some countries, prenatal diagnosis and selective
abortion reduce the number of b-thalassemia births. Early
treatment is preferable to adult treatment because the former
requires fewer cells than the latter. Hence, iPS cell therapy
may contribute to effective treatment of this disease in the peri-
natal period. Generation of iPS cell lines from human Fanconi
anemia (FA) patients and gene-corrected FA-iPS cell lines
demonstrated the possibility of acquiring disease-corrected,
patient-specific cells (Raya et al., 2009).
Retinal cells are the most accessible part of the central ner-
vous system and provide an ideal platform for the evaluation of
the therapeutic potential of iPS cells in clinical settings. Human
iPS cells can be maintained and directed to differentiate into
retinal cell types under xeno-free conditions (Sridhar et al.,
2013). Retinal cells rarely develop cancers, and, even if a tumor
arises, it can easily be removed with a laser-based procedure.
Taking these advantages into consideration, Masayo Takahashi
has announced a clinical trial to treat age-related macular
degeneration, which is a common cause of blindness that affects
at least 1% of people older than 50 years of age (http://www.
riken.jp/en/pr/press/2013/20130730_1/; see also Cyranoski,
2013). Researchers hope that this trial is successful, as it will
show that iPS cells could be used in the clinic.
Using mouse cells, Zhao and colleagues demonstrated the
iPS-mediated induction of T cell–dependent immune response
in syngeneic recipients, suggesting the requirement of careful
validation before clinical trials (Zhao et al., 2011). In contrast,
Araki and colleagues showed that in regressing skin and tera-
toma tissues of mice, transplanted cells differentiated from iPS
cells and that ESCs triggered a limited or no immune responseAll rights reserved
Figure 4. Potential of Chromatin-Remodeling Pyrrole-Imidazole Polyamides to Generate CGiPS Cells
(A) Several deviations exist in the conventional route to switch laboratory-grade iPS cells to CGiPS cells. In the box, some major drawbacks get illustrated as
roadblocks as in Barrilleaux and Knoepfler (2011).
(B) The development of multifactor-targeting small molecules, such as chromatin-remodeling pyrrole–imidazole polyamide (PIP), that could selectively and
concomitantly switch the essential genes/factors ‘‘ON’’ and ‘‘OFF’’ may lead to the generation of CGiPS cells.
Chemistry & Biology
Review(Araki et al., 2013). The genomic integrity of iPS cells is another
concern, as iPS cells have more copy number variations
(CNVs) in their genomes than ESCs or their parental fibroblasts
in human cells (Hussein et al., 2011). However, Abyzov and
colleagues implied that reprogramming does not necessarily
lead to de novo CNVs in iPS cells, because most of the line-
manifested CNVs reflect somatic mosaicism in the human skin
(Abyzov et al., 2012). Hence, iPS cells could be as useful as
ESCs in human cells.
Conclusions
Development of tailor-made therapeutics is the ultimate goal of
the use of iPS cells. In this context, small molecules have the
advantage, as they can be designed and optimized according
to the patient’s needs. Small molecules have shown successChemistry & Biology 2in obviating the need for retroviruses, and complete chemical re-
programming has now been achieved in mouse cells. However,
at least one transcription factor, such as OCT4, is essential for
the generation of iPS cells using human cells. Although small
molecules increase reprogramming efficiency, the overall effi-
ciency of this approach remains lower than that observed with
the use of mRNA-based induction protocols. The populations
of nonresponsive or stochastically resistant fibroblasts may
outnumber those that are responsive to the reprogramming
protocol. Some other unknown factors could also play a key
role in improving the efficiency of reprogramming. Therefore,
the development of different types of multitarget small mole-
cules, such as SAHA-PIP, that could rapidly induce multiple
pluripotency in somatic cells via site-specific epigenetic activa-
tion is relevant, as the genomewide gene expression profile0, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1319
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Reviewand acetylation pattern of SAHA-PIP-treated cells were compa-
rable to those seen in ESCs (Pandian et al., 2012a). Epigenetic
reprogramming could also be the key to improving the clinical
utility of iPS cells (Fisher and Merkenschlager, 2010). Studies
in human cells suggested that significant regions of the iPS epi-
genome do not revert to the embryonic state; rather, they retain
the epigenetic memory of their tissue of origin (Lister et al., 2011).
Chromatin-modifying enzymes could act as both facilitators of
and barriers to the epigenetic remodeling of differentiated cells
into a stem cell configuration in mouse and human cells (Hirai
et al., 2011; Onder et al., 2012). Therefore, small molecules,
such as SAHA-PIPs, that can induce sequence-specific chro-
matin modifications (Han et al., 2013) need to be developed to
erase the epigenetic memory and aid the generation of CGiPS
cells. Although SAHA-PIP research is in its primitive stage, the
development of such innovative small-molecule-based strate-
gies may offer new opportunities to transfer the iPS cell technol-
ogy from the laboratory to the clinic as shown in Figure 4.
Identification of a small-molecule, pluripotent cell-specific
inhibitor (PluriSIn#1; N0-phenylisonicotinohydrazide) that selec-
tively eliminated human pluripotent cells substantiated the
opportunities to develop demand-based small molecules via
screening (Ben-David et al., 2013). Although exciting advance-
ments in developing chemical biology tools are taking place at
an astonishing pace, careful validation is needed to minimize
safety concerns. Nevertheless, innovative strategies and optimal
cell sources will likely allow the efficient generation of CGiPS
cells in the near future.
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